Changes in bone biomarkers in response to different dosing regimens of cholecalciferol supplementation in children with chronic kidney disease.
Bone biomarkers
Children
Cholecalciferol
Chronic kidney disease
Vitamin D
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
27
07
2022
accepted:
10
10
2022
revised:
08
10
2022
medline:
4
5
2023
pubmed:
3
11
2022
entrez:
2
11
2022
Statut:
ppublish
Résumé
The effect of different dosing regimens of cholecalciferol supplementation on bone biomarkers has not been studied in children with chronic kidney disease (CKD). This is a post hoc analysis of a multi-center randomized controlled trial which included children with CKD stages 2-4 with vitamin D deficiency (25-hydroxy vitamin D (25OHD) < 30 ng/ml) randomized 1:1:1 to receive an equivalent dose of oral cholecalciferol as daily, weekly or monthly treatment. Markers of bone formation (bone alkaline phosphatase (BAP), procollagen I N terminal peptide (PINP)), bone resorption (tartarate-resistant acid phosphatase 5b (TRAP), C terminal telopeptide (CTX)), and osteocyte markers (intact fibroblast growth factor 23 (iFGF23), sclerostin) and soluble klotho were measured at baseline and after 3 months of intensive replacement therapy. The change in biomarkers and ratio of markers of bone formation to resorption were compared between treatment arms. BAP and TRAP were expressed as age- and sex-specific z-scores. 25OHD levels increased with cholecalciferol supplementation, with 85% achieving normal levels. There was a significant increase in the BAP/TRAP ratio (p = 0.04), iFGF23 (p = 0.004), and klotho (p = 0.002) with cholecalciferol therapy, but this was comparable across all three therapy arms. The BAPz was significantly higher in the weekly arm (p = 0.01). The change in 25OHD (Δ25OHD) inversely correlated with ΔPTH (r = - 0.4, p < 0.001). Although cholecalciferol supplementation was associated with a significant increase in bone formation, the three dosing regimens of cholecalciferol supplementation have a comparable effect on the bone biomarker profile, suggesting that they can be used interchangeably to suit the patient's needs and optimize adherence to therapy. A higher resolution version of the Graphical abstract is available as Supplementary information.
Sections du résumé
BACKGROUND
The effect of different dosing regimens of cholecalciferol supplementation on bone biomarkers has not been studied in children with chronic kidney disease (CKD).
METHODS
This is a post hoc analysis of a multi-center randomized controlled trial which included children with CKD stages 2-4 with vitamin D deficiency (25-hydroxy vitamin D (25OHD) < 30 ng/ml) randomized 1:1:1 to receive an equivalent dose of oral cholecalciferol as daily, weekly or monthly treatment. Markers of bone formation (bone alkaline phosphatase (BAP), procollagen I N terminal peptide (PINP)), bone resorption (tartarate-resistant acid phosphatase 5b (TRAP), C terminal telopeptide (CTX)), and osteocyte markers (intact fibroblast growth factor 23 (iFGF23), sclerostin) and soluble klotho were measured at baseline and after 3 months of intensive replacement therapy. The change in biomarkers and ratio of markers of bone formation to resorption were compared between treatment arms. BAP and TRAP were expressed as age- and sex-specific z-scores.
RESULTS
25OHD levels increased with cholecalciferol supplementation, with 85% achieving normal levels. There was a significant increase in the BAP/TRAP ratio (p = 0.04), iFGF23 (p = 0.004), and klotho (p = 0.002) with cholecalciferol therapy, but this was comparable across all three therapy arms. The BAPz was significantly higher in the weekly arm (p = 0.01). The change in 25OHD (Δ25OHD) inversely correlated with ΔPTH (r = - 0.4, p < 0.001).
CONCLUSIONS
Although cholecalciferol supplementation was associated with a significant increase in bone formation, the three dosing regimens of cholecalciferol supplementation have a comparable effect on the bone biomarker profile, suggesting that they can be used interchangeably to suit the patient's needs and optimize adherence to therapy. A higher resolution version of the Graphical abstract is available as Supplementary information.
Identifiants
pubmed: 36322258
doi: 10.1007/s00467-022-05790-0
pii: 10.1007/s00467-022-05790-0
doi:
Substances chimiques
Cholecalciferol
1C6V77QF41
Biomarkers
0
Alkaline Phosphatase
EC 3.1.3.1
Types de publication
Randomized Controlled Trial
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1907-1913Informations de copyright
© 2022. The Author(s), under exclusive licence to International Pediatric Nephrology Association.
Références
Altemose KE, Kumar J, Portale AA, Warady BA, Furth SL, Fadrowski JJ et al (2018) Vitamin D insufficiency, hemoglobin, and anemia in children with chronic kidney disease. Pediatr Nephrol 33:2131–2136. https://doi.org/10.1007/s00467-018-4020-5
doi: 10.1007/s00467-018-4020-5
pubmed: 30008129
pmcid: 6528819
Doyon A, Fischer DC, Bayazit AK, Canpolat N, Duzova A, Sözeri B et al (2015) Markers of bone metabolism are affected by renal function and growth hormone therapy in children with chronic kidney disease. PLoS One 10:e0113482. https://doi.org/10.1371/journal.pone.0113482
doi: 10.1371/journal.pone.0113482
pubmed: 25659076
pmcid: 4319910
Aytaç MB, Deveci M, Bek K, Kayabey Ö, Ekinci Z (2016) Effect of cholecalciferol on local arterial stiffness and endothelial dysfunction in children with chronic kidney disease. Pediatr Nephrol 31:267–277. https://doi.org/10.1007/s00467-015-3220-5
doi: 10.1007/s00467-015-3220-5
pubmed: 26432706
Kaur G, Singh J, Kumar J (2019) Vitamin D and cardiovascular disease in chronic kidney disease. Pediatr Nephrol 34:2509–2522. https://doi.org/10.1007/s00467-018-4088-y
doi: 10.1007/s00467-018-4088-y
pubmed: 30374603
Shroff R, Aitkenhead H, Costa N, Trivelli A, Litwin M, Picca S, et al ESCAPE Trial Group (2016) Normal 25-hydroxyvitamin D levels are associated with less proteinuria and attenuate renal failure progression in children with CKD. J Am Soc Nephrol 27:314–322. https://doi.org/10.1681/ASN.2014090947
doi: 10.1681/ASN.2014090947
pubmed: 26069294
Shroff R, Wan M, Nagler EV, Bakkaloglu S, Fischer DC, Bishop N, et al European Society for Paediatric Nephrology Chronic Kidney Disease Mineral and Bone Disorders and Dialysis Working Groups et al (2017) Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease Stages 2–5 and on dialysis. Nephrol Dial Transplant 32:1098–1113. https://doi.org/10.1093/ndt/gfx065
doi: 10.1093/ndt/gfx065
pubmed: 28873969
pmcid: 5837199
Stein DR, Feldman HA, Gordon CM (2012) Vitamin D status in children with chronic kidney disease. Pediatr Nephrol 27:1341–1350. https://doi.org/10.1007/s00467-012-2143-7
doi: 10.1007/s00467-012-2143-7
pubmed: 22453735
pmcid: 3749087
Hari P, Gupta N, Hari S, Gulati A, Mahajan P, Bagga A (2010) Vitamin D insufficiency and effect of cholecalciferol in children with chronic kidney disease. Pediatr Nephrol 25:2483–2488. https://doi.org/10.1007/s00467-010-1639-2
doi: 10.1007/s00467-010-1639-2
pubmed: 20872152
Shroff R, Wan M, Gullett A, Ledermann S, Shute R, Knott C et al (2012) Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial. Clin J Am Soc Nephrol 7:216–223. https://doi.org/10.2215/CJN.04760511
doi: 10.2215/CJN.04760511
pubmed: 22266572
Lerch C, Shroff R, Wan M, Rees L, Aitkenhead H, Kaplan Bulut I et al (2018) 4C Study Consortium; ESPN CKD-MBD Working group effects of nutritional vitamin D supplementation on markers of bone and mineral metabolism in children with chronic kidney disease. Nephrol Dial Transplant 33:2208–2217. https://doi.org/10.1093/ndt/gfy012
Iyengar A, Kamath N, Reddy HV, Sharma J, Singhal J, Uthup S et al (2022) Determining the optimal cholecalciferol dosing regimen in children with CKD: a randomized controlled trial. Nephrol Dial Transplant 37:326–334. https://doi.org/10.1093/ndt/gfaa369
doi: 10.1093/ndt/gfaa369
pubmed: 33367869
Fischer DC, Mischek A, Wolf S, Rahn A, Salweski B, Kundt G et al (2012) Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase. Ann Clin Biochem 49:546–553. https://doi.org/10.1258/acb.2012.011274
doi: 10.1258/acb.2012.011274
pubmed: 22984195
Shroff R, Fewtrell M, Heuser A, Kolevica A, Lalayiannis A, McAlister L et al (2021) Naturally occurring stable calcium isotope ratios in body compartments provide a novel biomarker of bone mineral balance in children and young adults. J Bone Miner Res 36:133–142. https://doi.org/10.1002/jbmr.4158
doi: 10.1002/jbmr.4158
pubmed: 32786145
Lalayiannis AD, Crabtree NJ, Fewtrell M, Biassoni L, Milford DV, Ferro CJ, Shroff R (2020) Assessing bone mineralisation in children with chronic kidney disease: what clinical and research tools are available? Pediatr Nephrol 35:937–957. https://doi.org/10.1007/s00467-019-04271-1
doi: 10.1007/s00467-019-04271-1
pubmed: 31240395
Chiang C (2017) The use of bone turnover markers in chronic kidney disease-mineral and bone disorders. Nephrology 22(Suppl 2):11–13. https://doi.org/10.1111/nep.13014
doi: 10.1111/nep.13014
pubmed: 28429547
Fischer DC, Smith C, De Zan F, Bacchetta J, Bakkaloglu SA, Agbas A et al (2021) Hemodiafiltration is associated with reduced inflammation and increased bone formation compared with conventional hemodialysis in children: the HDF, Hearts and Heights (3H) study. Kidney Int Rep 6:2358–2370. https://doi.org/10.1016/j.ekir.2021.06.025
doi: 10.1016/j.ekir.2021.06.025
pubmed: 34514197
pmcid: 8418977
Bikle DD (2012) Vitamin D and bone. Curr Osteoporos Rep 10:151–159. https://doi.org/10.1007/s11914-012-0098-z
doi: 10.1007/s11914-012-0098-z
pubmed: 22544628
pmcid: 3688475
Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B et al (2009) Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 94:511–517. https://doi.org/10.1210/jc.2008-0326
doi: 10.1210/jc.2008-0326
pubmed: 19050056
Wan M, Smith C, Shah V, Gullet A, Wells D, Rees L, Shroff R (2013) Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease. Nephrol Dial Transplant 28:153–161. https://doi.org/10.1093/ndt/gfs411
doi: 10.1093/ndt/gfs411
pubmed: 23180879
Yadav AK, Kumar V, Kumar V, Banerjee D, Gupta KL, Jha V (2018) The effect of vitamin D supplementation on bone metabolic markers in chronic kidney disease. J Bone Miner Res 33:404–409. https://doi.org/10.1002/jbmr.3314
doi: 10.1002/jbmr.3314
pubmed: 29044707
Gravesen E, Hofman-Bang J, Lewin E, Olgaard K (2013) Ergocalciferol treatment and aspects of mineral homeostasis in patients with chronic kidney disease stage 4–5. Scand J Clin Lab Invest 73:107–116. https://doi.org/10.3109/00365513.2012.744464
doi: 10.3109/00365513.2012.744464
pubmed: 23281842